Evaluation of silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
Author(s):
Article Type:
Research/Original Article (دارای رتبه معتبر)
Abstract:
Aim
This study was performed to evaluate the potential efficacy of silymarin in the management of anti-tuberculosis medication’s induced liver injury.
Background
Hepatic toxicity is the most serious complication in treatment of tuberculosis.
Methods
In a randomized double blind clinical trial (ACTRN12610000643077), 55 cases with hepatotoxicity caused by anti-tuberculosis drugs were divided into two groups. Informed consents were obtained. The intervention group received silymarin and the control group received placebo. Severity of liver injury, the duration necessary for normalization of liver function and hospital stay were compared between the two groups.
Results
There was not any statistically significant difference in the rate of adverse effects between silymarin and placebo groups.
Conclusion
Although silymarin is considered a safe herbal medication, it was not effective to treat hepatic toxicity of anti-tuberculosis drugs.Keywords: Tuberculosis, Adverse effects, Silymarin, Drug induced hepatitis.(Please cite as: Marjani M, Fahimi F, Sadr M, Kazempour Dizaji M, Moniri A, Shadi Khabiri6, et al. Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial. Gastroenterol Hepatol Bed Bench 2019;12(2):138-142).Keywords:
Language:
English
Published:
Gastroenterology and Hepatology From Bed to Bench Journal, Volume:12 Issue: 2, Spring 2019
Pages:
138 to 142
https://magiran.com/p1973067
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یکساله به مبلغ 1,390,000ريال میتوانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.
In order to view content subscription is required
Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!